Balance Sheet (Annual)

QCP / Quality Care Properties, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2016 2017
Assets
  Real Estate Investment Property Net
    Investment Building And Building Improvements 4,891,996 4,289,798
    Land 637,601 585,559
    Real Estate Investment Property Accumulated Depreciation 1,111,768 991,731
    Real Estate Investment Property Net 4,417,829 3,883,626
  Real Estate Heldforsale - -
  Cash And Cash Equivalents At Carrying Value 126,185 325,587
  Restricted Cash And Cash Equivalents 17 24
  Intangible Assets Net Excluding Goodwill 199,745 158,072
  Deferred Rent Receivables Net 3,296 2,462
  Other Assets 26,284 22,293
  Assets 4,789,375 4,392,064
Liabilities And Stockholders Equity
  Line Of Credit 25,000 75,000
  Loans Payable 957,465 953,768
  Senior Notes 730,604 733,412
  Security Deposit Liability And Deferred Revenue And Credits 5,587 8,029
  Interest Payable Current And Noncurrent 12,526 10,548
  Accounts Payable And Accrued Liabilities Current And Noncurrent 4,426 10,117
  Liabilities 1,752,152 1,790,874
  Redeemable Noncontrolling Interest Equity Preferred Carrying Amount 1,930 1,930
  Stockholders Equity
    Common Stock Value 936 938
    Additional Paid In Capital 3,163,954 3,171,460
    Retained Earnings Accumulated Deficit -130,094 -573,635
    Stockholders Equity 3,034,796 2,598,763
    Minority Interest 497 497
    Stockholders Equity Including Portion Attributable To Noncontrolling Interest 3,035,293 2,599,260
  Liabilities And Stockholders Equity 4,789,375 4,392,064

Peers -

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 747545101